Our data from single and combinatorial drug screens show that inhibitors of Bcl-2 and BTK or PI3K act synergistically to kill DLBCL cells that exhibit high Bcl-2 expression due to either BCL2 translocations or amplifications. The gene discussed is BTK; the disease is diffuse large B-cell lymphoma.